MRGPRX2
Mas-related G-protein coupled receptor member X2
Protein Summary
Mast cell-specific receptor for basic secretagogues, i.e. cationic amphiphilic drugs, as well as endo- or exogenous peptides, consisting of a basic head group and a hydrophobic core (PubMed:25517090). Recognizes and binds small molecules containing a cyclized tetrahydroisoquinoline (THIQ), such as non-steroidal neuromuscular blocking drugs (NMBDs), including tubocurarine and atracurium. In response to these compounds, mediates pseudo-allergic reactions characterized by histamine release, inflammation and airway contraction (By similarity). Acts as a receptor for a number of other ligands, including peptides and alkaloids, such as cortistatin-14, proadrenomedullin N-terminal peptides PAMP-12 and, at lower extent, PAMP-20, antibacterial protein LL-37, PMX-53 peptide, beta-defensins, and complanadine A.
- ENST00000329773
- ENSP00000333800
- ENSG00000183695
- MRGX2
- MGRG3
- MRGX2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
gene perturbation | 0.88 | ||
protein domain | 0.58 | ||
cell type or tissue | 0.56 | ||
biological process | 0.46 | ||
ligand (protein) | 0.46 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 187.32 (req: < 5)
Gene RIFs: 56 (req: <= 3)
Antibodies: 269 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 187.32 (req: >= 5)
Gene RIFs: 56 (req: > 3)
Antibodies: 269 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 9
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 4
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0